CARA - Cara Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 51.1B
Enterprise Value 3973.32M
Trailing P/E N/A
Forward P/E 1-10.59
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)54.57
Price/Book (mrq)9.54
Enterprise Value/Revenue 348.22
Enterprise Value/EBITDA 6-10.88

Trading Information

Stock Price History

Beta (3Y Monthly) 2.02
52-Week Change 323.41%
S&P500 52-Week Change 31.11%
52 Week High 327.55
52 Week Low 312.19
50-Day Moving Average 323.55
200-Day Moving Average 319.85

Share Statistics

Avg Vol (3 month) 3896.5k
Avg Vol (10 day) 3611.42k
Shares Outstanding 5N/A
Float 42.06M
% Held by Insiders 12.87%
% Held by Institutions 162.37%
Shares Short (Jul 31, 2019) 45.98M
Short Ratio (Jul 31, 2019) 45.56
Short % of Float (Jul 31, 2019) 415.48%
Short % of Shares Outstanding (Jul 31, 2019) 412.99%
Shares Short (prior month Jun 28, 2019) 46.38M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 22/1
Last Split Date 3Jan 16, 2014

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-444.49%

Management Effectiveness

Return on Assets (ttm)-38.73%
Return on Equity (ttm)-98.45%

Income Statement

Revenue (ttm)20.18M
Revenue Per Share (ttm)0.51
Quarterly Revenue Growth (yoy)81.20%
Gross Profit (ttm)-62.06M
EBITDA -89.49M
Net Income Avi to Common (ttm)-84.97M
Diluted EPS (ttm)-2.17
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)115.31M
Total Cash Per Share (mrq)2.48
Total Debt (mrq)4.77M
Total Debt/Equity (mrq)4.79
Current Ratio (mrq)3.11
Book Value Per Share (mrq)2.49

Cash Flow Statement

Operating Cash Flow (ttm)-97.28M
Levered Free Cash Flow (ttm)-41.7M